Key result
TAVI in low-risk patients raises concerns for long-term durability, late mortality, and higher reintervention vs SAVR.
Why the study?
Expanding use of TAVI in low-risk severe aortic stenosis makes extended follow-up from TAVI versus SAVR trials essential to evaluate valve durability, late adverse events, and lifetime management.
Does TAVI compared to SAVR provide durable and safe long-term outcomes in low-risk patients with severe aortic stenosis?
Does TAVI compared to SAVR provide durable and safe long-term outcomes in low-risk patients with severe aortic stenosis?
Extended follow-up of TAVI versus SAVR trials in low-risk patients raises concerns about long-term durability and late adverse events, emphasizing the need for caution and individualized lifetime management strategies.
Answers are grounded in this paper and cite their sources.
Extended TAVI-SAVR follow-up remains essential for low-risk durability assessment; 6- to 7-year data leave late events open for confirmation.
The expanding use of transcatheter aortic valve implantation (TAVI) in low-risk patients with severe aortic stenosis, including populations underrepresented in pivotal trials and often beyond established guideline recommendations, makes extended follow-up from TAVI versus surgical aortic valve replacement (SAVR) trials central to assessing valve durability and late adverse events and to informing lifetime management strategy. Although Evolut Low Risk 6- to 7-year follow-up showed no statistically significant difference in the primary composite of death or disabling stroke, the signals of later mortality accrual, more myocardial infarction events, and higher aortic valve reintervention rates with TAVI raise concerns about durability and stability of the early treatment effect. In PARTNER 3, 7-year outcomes appeared broadly similar when comparing the reported composite endpoints, but their interpretation is limited by heterogeneous endpoint construction, non-prespecified hierarchical analysis, incomplete follow-up, and the influence of post hoc vital-status ascertainment on late mortality estimates. In an intermediate-risk population, PARTNER 2A showed lower 10-year survival and higher aortic valve reintervention rates with TAVI than with SAVR. Together with the presented UK-TAVI, meta-analyses, and large observational studies, these findings underscore uncertainty about durability and reintervention burden of TAVI and future treatment strategies. By integrating extended follow-up from pivotal trials with other new data, this review calls for a more rigorous and transparent long-term evidence framework before further expanding TAVI, particularly in younger, low-risk patients. Treatment decisions should remain individualized within a structured Heart Team framework, with explicit discussion of expected survival, anatomical suitability, valve durability, reintervention options, and lifetime-management implications.
No takes yet. Share an insight, caveat, or question.
Uva et al. (2026) conducted a review in Severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve implantation in low-risk patients raises concerns regarding long-term valve durability, late mortality accrual, and higher reintervention rates compared to surgery.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: